Because PILL is a leveraged ETF rather than an operating company, it does not attract the traditional analyst price targets that individual stocks do. There is no credible, current sell-side consensus to aggregate for this fund. Instead, the $20 level is best understood as a technical and psychological reference point drawn from public market commentary and price-chart analysis. I also checked this using Tickeron’s AI Pattern Search Engine to see how the current setup compares with past patterns.
The $20 mark is a round-number psychological level that has appeared in public discussion of the fund's upside. Above it, the fund's 52-week high of $24.15, set in August 2026, stands as a more demanding resistance zone. The $20 objective should therefore be read as a level traders and commentators are watching, not as a published analyst consensus or a forecast of where the fund will trade.
PILL has recently traded near $14.55, in the lower half of a 52-week range that stretches from $7.74 to $24.15. Reaching $20 would require a rise of about 37% from that level, a substantial move. The path would depend overwhelmingly on the performance of the underlying S&P Pharmaceuticals Select Industry Index, a modified equal-weighted gauge of U.S. pharmaceutical and medical companies, amplified by the fund's 3x daily leverage.
Because the leverage resets each day, the relationship between the index's return and PILL's return is not one-for-one over time. In a smooth, trending advance, the fund can capture roughly three times the daily move; in choppy, sideways conditions, daily rebalancing erodes value through volatility decay. Any move toward $20 would likely require a sustained, low-volatility uptrend in pharmaceutical stocks rather than a sharp but brief rally.
The underlying index delivered strong returns of roughly 24% in 2024 and 17% in 2025, a backdrop that historically helps leveraged long products. Structural demand from an aging population, continued research and development spending, and commercial momentum in obesity and oncology medicines all support the pharmaceutical sector's long-term case. From what I see, a return to a trending, lower-volatility regime would be the key enabler for PILL.
When daily moves are consistently positive, the 3x multiplier compounds favorably. Favorable Food and Drug Administration decisions, product approvals, and solid quarterly earnings from major pharmaceutical companies could reinforce such a trend, as could a broader rotation into defensive healthcare names if equity markets turn cautious.
The single largest obstacle is structural: PILL is designed to deliver 300% of a single day's index move, and holding it for weeks or months exposes investors to compounding decay. Even if the underlying index finishes a period flat, the fund can lose value from daily rebalancing in a volatile, range-bound market.
Additional headwinds include the fund's small asset base of roughly $13 million in assets under management (AUM), which contributes to a relatively wide bid-ask spread and higher trading costs, and a net expense ratio of 0.98%. Policy risk is also relevant: U.S. drug-pricing reforms and regulatory scrutiny can weigh on pharmaceutical valuations. Finally, the underlying index's momentum has been less consistent in 2026 than in the prior two years, a pattern that tends to aggravate leveraged-ETF decay.
The most important resistance above the current price is the 52-week high of $24.15, reached in August 2026. Before that, the $20 round-number level serves as an intermediate psychological barrier. On the downside, the October 2026 low near $13.25 is a meaningful support zone, with the May 2026 low near $10.66 and the 52-week low of $7.74 representing deeper support. The wide gap between these levels reflects the fund's exceptional volatility and the reason technical traders treat it as a short-term instrument.
Because PILL has no analyst targets, there is no formal research horizon attached to the $20 level; it is a technical reference rather than a dated forecast. Investors tracking this objective should monitor the direction and volatility of the underlying pharmaceutical index, quarterly earnings from major drugmakers, Food and Drug Administration approval decisions, and any progress or setbacks on U.S. drug-pricing legislation. Shifts in Federal Reserve rate expectations also matter, since lower rates have historically supported higher-multiple biotech and pharmaceutical valuations. Fund flows and changes in holdings are less informative here given the fund's small size and daily-reset design.
Can PILL reach $20? The level is attainable in percentage terms but is not a foregone conclusion. The $20 objective reflects public discussion and technical structure rather than an analyst consensus, and it would require a roughly 37% advance from recent levels. A sustained, low-volatility uptrend in U.S. pharmaceutical stocks, supported by innovation and favorable policy or rate conditions, could power such a move. Conversely, daily-reset leverage, volatility decay, thin liquidity, and an uneven 2026 tape for the underlying index all argue for caution. Investors should watch the underlying index's trend, sector earnings, regulatory developments, and rate expectations, and should treat PILL as a short-term trading vehicle rather than a long-term holding.
In my analysis of leveraged products like PILL, timing and trend recognition matter a great deal. I have found Tickeron's AI Daily Buy/Sell Signals helpful for monitoring thousands of stocks and ETFs in real time. The tool generates Buy, Sell, or Hold signals based on technical behavior and market conditions, which can complement independent research when navigating high-volatility instruments.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
PILL saw its Momentum Indicator move below the 0 level on November 20, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 83 similar instances where the indicator turned negative. In 75 of the 83 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
The Moving Average Convergence Divergence Histogram (MACD) for PILL turned negative on November 18, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 46 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
PILL moved below its 50-day moving average on November 16, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PILL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
PILL broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where PILL's RSI Oscillator exited the oversold zone, 28 of 28 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
The 10-day moving average for PILL crossed bullishly above the 50-day moving average on November 16, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 83%.
Following a +6.77% 3-day Advance, the price is estimated to grow further. Considering data from situations where PILL advanced for three days, in 288 of 311 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.
The Aroon Indicator entered an Uptrend today. In 199 of 213 cases where PILL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows